McKessonMCK

About McKesson

McKesson Corporation is one of the largest pharmaceutical distributors in the world, moving branded, generic, and specialty drugs from manufacturers to pharmacies, hospitals, and clinics across the United States and internationally. Its business is organized primarily around U.S. Pharmaceutical distribution, Prescription Technology Solutions, Medical-Surgical Solutions, and an International segment centered on Canada after the divestiture of most European operations. U.S. Pharmaceutical, which serves large retail chains, independent pharmacies, hospital systems, and mail-order operators, generates the overwhelming majority of consolidated revenue but at very thin gross margins characteristic of drug wholesaling. Specialty distribution and provider-facing technology services, though smaller in revenue, contribute a disproportionate share of operating profit given their higher-margin economics.

Serious holders track a familiar set of structural questions. Customer concentration is unusually high: a handful of national pharmacy chains and pharmacy benefit managers account for a large slice of revenue, giving counterparties significant negotiating leverage on distribution economics. Supplier concentration on the manufacturer side, generic pricing dynamics, and the ClarusONE sourcing joint venture with Walmart also shape margins. Regulatory exposure spans the DEA controlled-substances regime, ongoing opioid-settlement obligations under a multi-state framework, and Medicare and 340B policy shifts. Governance and capital allocation lean toward consistent share repurchases and a modest dividend, funded by working-capital-light cash generation. Cyclicality is limited, but reimbursement policy and specialty drug launch cadence drive year-to-year variability.

The company traces its origins to 1833, when Charles Olcott and John McKesson opened a wholesale drug and chemicals business in New York, making it one of the oldest continuously operating firms in American healthcare. It evolved through the twentieth century as Foremost-McKesson, later refocused on healthcare distribution, and adopted the McKesson HBOC name after its 1999 acquisition of information-technology firm HBO & Company, an episode that produced a major accounting restatement. The subsequent decades brought expansion into medical-surgical distribution through the 2003 purchase of Moore Medical and the 2012 acquisition of PSS World Medical, international scale via the 2014 Celesio deal, and specialty and technology build-outs, followed by the 2020 spin-off of Change Healthcare and exits from most European markets.

Mechanically, McKesson buys pharmaceuticals in bulk from manufacturers, warehouses them in a national network of distribution centers, and delivers to dispensing customers under multi-year supply contracts that typically compensate the distributor through a mix of fee-for-service payments from manufacturers and small markups over acquisition cost. Buy-side generic sourcing scale, working-capital management, and logistics density are the core competitive levers, alongside value-added services in specialty logistics, oncology practice support through US Oncology Network, and prescription routing technology. It competes primarily with Cencora and Cardinal Health in a stable domestic oligopoly, with Canada representing a meaningful minority of revenue and the United States providing the clear majority.

Company profile by LineVest editorial. Journalism, not investment advice. Commission a full SEC-based report on McKesson →